Martin Gritter1, Rosa D Wouda2, Stanley M H Yeung3, Michiel L A Wieërs1, Frank Geurts1, Maria A J de Ridder4, Christian R B Ramakers5, Liffert Vogt2, Martin H de Borst3, Joris I Rotmans6, Ewout J Hoorn. 1. Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, The Netherlands. 2. Division of Nephrology, Amsterdam University Medical Center, Amsterdam, The Netherlands. 3. Division of Nephrology, University Medical Center Groningen, Groningen, The Netherlands. 4. Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands. 5. Department of Clinical Chemistry, Erasmus Medical Center, Rotterdam, The Netherlands. 6. Department of Internal Medicine, Division of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.
Abstract
BACKGROUND: Observational studies suggest that adequate dietary potassium intake (90-120 mmol/day) may be renoprotective, but the effects of increasing dietary potassium and the risk of hyperkalemia are unknown. METHODS: This is a prespecified analysis of the run-in phase of a clinical trial in which 191 patients (age 68±11 years, 74% males, 86% European ancestry, eGFR 31±9 ml/min per 1.73 m2, 83% renin-angiotensin system inhibitors, 38% diabetes) were treated with 40 mmol potassium chloride (KCl) per day for 2 weeks. RESULTS: KCl supplementation significantly increased urinary potassium excretion (72±24 to 107±29 mmol/day), plasma potassium (4.3±0.5 to 4.7±0.6 mmol/L), and plasma aldosterone (281 [198-431] to 351 [241-494] ng/L), but had no significant effect on urinary sodium excretion, plasma renin, BP, eGFR, or albuminuria. Furthermore, KCl supplementation increased plasma chloride (104±3 to 105±4 mmol/L) and reduced plasma bicarbonate (24.5±3.4 to 23.7±3.5 mmol/L) and urine pH (all P<0.001), but did not change urinary ammonium excretion. In total, 21 participants (11%) developed hyperkalemia (plasma potassium 5.9±0.4 mmol/L). They were older and had higher baseline plasma potassium. CONCLUSIONS: In patients with CKD stage G3b-4, increasing dietary potassium intake to recommended levels with potassium chloride supplementation raises plasma potassium by 0.4 mmol/L. This may result in hyperkalemia in older patients or those with higher baseline plasma potassium. Longer-term studies should address whether cardiorenal protection outweighs the risk of hyperkalemia.Clinical trial number: NCT03253172.
BACKGROUND: Observational studies suggest that adequate dietary potassium intake (90-120 mmol/day) may be renoprotective, but the effects of increasing dietary potassium and the risk of hyperkalemia are unknown. METHODS: This is a prespecified analysis of the run-in phase of a clinical trial in which 191 patients (age 68±11 years, 74% males, 86% European ancestry, eGFR 31±9 ml/min per 1.73 m2, 83% renin-angiotensin system inhibitors, 38% diabetes) were treated with 40 mmol potassium chloride (KCl) per day for 2 weeks. RESULTS: KCl supplementation significantly increased urinary potassium excretion (72±24 to 107±29 mmol/day), plasma potassium (4.3±0.5 to 4.7±0.6 mmol/L), and plasma aldosterone (281 [198-431] to 351 [241-494] ng/L), but had no significant effect on urinary sodium excretion, plasma renin, BP, eGFR, or albuminuria. Furthermore, KCl supplementation increased plasma chloride (104±3 to 105±4 mmol/L) and reduced plasma bicarbonate (24.5±3.4 to 23.7±3.5 mmol/L) and urine pH (all P<0.001), but did not change urinary ammonium excretion. In total, 21 participants (11%) developed hyperkalemia (plasma potassium 5.9±0.4 mmol/L). They were older and had higher baseline plasma potassium. CONCLUSIONS: In patients with CKD stage G3b-4, increasing dietary potassium intake to recommended levels with potassium chloride supplementation raises plasma potassium by 0.4 mmol/L. This may result in hyperkalemia in older patients or those with higher baseline plasma potassium. Longer-term studies should address whether cardiorenal protection outweighs the risk of hyperkalemia.Clinical trial number: NCT03253172.
Authors: Robert M Rosa; Ernest De Jesus; Kevin Sperling; Annie Suh; Aleksandra Gmurczyk; Kevin A Myrie; Karol Rosner; Edgar Lerma; William Yu; Richard Breuer; James B Young Journal: J Hypertens Date: 2012-12 Impact factor: 4.844
Authors: Juan J Carrero; Ailema González-Ortiz; Carla M Avesani; Stephan J L Bakker; Vincenzo Bellizzi; Philippe Chauveau; Catherine M Clase; Adamasco Cupisti; Angeles Espinosa-Cuevas; Pablo Molina; Karine Moreau; Giorgina B Piccoli; Adrian Post; Siren Sezer; Denis Fouque Journal: Nat Rev Nephrol Date: 2020-06-11 Impact factor: 28.314
Authors: Christiane I Ramos; Ailema González-Ortiz; Angeles Espinosa-Cuevas; Carla M Avesani; Juan Jesus Carrero; Lilian Cuppari Journal: Nephrol Dial Transplant Date: 2021-11-09 Impact factor: 5.992
Authors: Jiang He; Katherine T Mills; Lawrence J Appel; Wei Yang; Jing Chen; Belinda T Lee; Sylvia E Rosas; Anna Porter; Gail Makos; Matthew R Weir; L Lee Hamm; John W Kusek Journal: J Am Soc Nephrol Date: 2015-09-17 Impact factor: 10.121
Authors: Csaba P Kovesdy; Kunihiro Matsushita; Yingying Sang; Nigel J Brunskill; Juan J Carrero; Gabriel Chodick; Takeshi Hasegawa; Hiddo L Heerspink; Atsushi Hirayama; Gijs W D Landman; Adeera Levin; Dorothea Nitsch; David C Wheeler; Josef Coresh; Stein I Hallan; Varda Shalev; Morgan E Grams Journal: Eur Heart J Date: 2018-05-01 Impact factor: 29.983